

# Nazareno Gonzalez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9102498/publications.pdf>

Version: 2024-02-01

13  
papers

282  
citations

1163117

8  
h-index

1199594

12  
g-index

13  
all docs

13  
docs citations

13  
times ranked

479  
citing authors

#	ARTICLE	IF	CITATIONS
1	Current Non-Viral Gene Therapy Strategies for the Treatment of Glioblastoma. <i>Current Medicinal Chemistry</i> , 2021, 28, 7729-7748.	2.4	1
2	Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 1045-1060.	3.4	7
3	VAV2 signaling promotes regenerative proliferation in both cutaneous and head and neck squamous cell carcinoma. <i>Nature Communications</i> , 2020, 11, 4788.	12.8	27
4	The role of the prolactin receptor pathway in the pathogenesis of glioblastoma: what do we know so far?. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1121-1133.	3.4	7
5	Computational and in vitro Pharmacodynamics Characterization of 1A-116 Rac1 Inhibitor: Relevance of Trp56 in Its Biological Activity. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 240.	3.7	7
6	Metal coordination and peripheral substitution modulate the activity of cyclic tetrapyrroles on $\text{I}\pm\text{S}$ aggregation: a structural and cell-based study. <i>Journal of Biological Inorganic Chemistry</i> , 2019, 24, 1269-1278.	2.6	2
7	Effects of alpha-synuclein post-translational modifications on metal binding. <i>Journal of Neurochemistry</i> , 2019, 150, 507-521.	3.9	60
8	Prolactin and its receptor as therapeutic targets in glioblastoma multiforme. <i>Scientific Reports</i> , 2019, 9, 19578.	3.3	19
9	Interaction of Cu(II) with the Met-X <sub>3</sub> -Met motif of alpha-synuclein: binding ligands, affinity and structural features. <i>Metallomics</i> , 2018, 10, 1383-1389.	2.4	16
10	Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells. <i>Frontiers in Oncology</i> , 2017, 7, 11.	2.8	24
11	Pharmacological Rac1 inhibitors with selective apoptotic activity in human acute leukemic cell lines. <i>Oncotarget</i> , 2017, 8, 98509-98523.	1.8	19
12	Preclinical Development of Novel Rac1-GEF Signaling Inhibitors using a Rational Design Approach in Highly Aggressive Breast Cancer Cell Lines. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 840-851.	1.7	67
13	Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells. <i>OncoTargets and Therapy</i> , 2014, 7, 2021.	2.0	26